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Summary
Fibroblast growth factor receptors (FGFRs) mediate a wide spectrum of cellular responses that are crucial for development and wound
healing. However, aberrant FGFR activity leads to cancer. Activated growth factor receptors undergo stimulated endocytosis, but can
continue to signal along the endocytic pathway. Endocytic trafficking controls the duration and intensity of signalling, and growth factor
receptor signalling can lead to modifications of trafficking pathways. We have developed live-cell imaging methods for studying FGFR
dynamics to investigate mechanisms that coordinate the interplay between receptor trafficking and signal transduction. Activated FGFR
enters the cell following recruitment to pre-formed clathrin-coated pits (CCPs). However, FGFR activation stimulates clathrin-mediated
endocytosis; FGF treatment increases the number of CCPs, including those undergoing endocytosis, and this effect is mediated by Src
and its phosphorylation target Eps8. Eps8 interacts with the clathrin-mediated endocytosis machinery and depletion of Eps8 inhibits
FGFR trafficking and immediate Erk signalling. Once internalized, FGFR passes through peripheral early endosomes en route to
recycling and degredative compartments, through an Src- and Eps8-dependent mechanism. Thus Eps8 functions as a key coordinator in
the interplay between FGFR signalling and trafficking. This work provides the first detailed mechanistic analysis of growth factor
receptor clustering at the cell surface through signal transduction and endocytic trafficking. As we have characterised the Src target Eps8
as a key regulator of FGFR signalling and trafficking, and identified the early endocytic system as the site of Eps8-mediated effects, this
work provides novel mechanistic insight into the reciprocal regulation of growth factor receptor signalling and trafficking.
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Introduction
Ligand-mediated activation of receptor tyrosine kinases (RTKs)
initiates a signal transduction cascade that leads to a broad
spectrum of cellular responses including differentiation,
proliferation, survival and migration. These responses are
initiated by recruitment of adaptors, scaffold and signalling
proteins to the phosphorylated cytoplasmic tail of the receptor
(Greenfield et al., 1989; Ullrich and Schlessinger, 1990; Heldin,
1995). Receptor activation also acts as the initiating stimulus for
endocytosis of RTKs following ligand binding and this can occur
via a variety of routes including both clathrin-mediated
endocytosis (CME) and clathrin-independent endocytosis (CIE)
(von Zastrow and Sorkin, 2007; Le Roy and Wrana, 2005).
Endocytosis and subsequent trafficking to intracellular
compartments have been considered to be principally
mechanisms of signal attenuation: the former by controlling the
number of receptors available for activation on the plasma
membrane, the latter by sorting the internalized receptors into the
intralumenal vesicles of multivescicular bodies (MVBs) where
receptor proteolysis takes place and signalling is terminated
(Stoscheck and Carpenter, 1984; Beguinot et al., 1984). There is
mounting evidence, however, that signalling from internalized
receptors persists along the endocytic pathway, and that
endocytosis and intracellular trafficking mechanisms have a
powerful influence on the spatial and temporal dynamics of the
signal (von Zastrow and Sorkin, 2007; Di Fiore and De Camilli,
2001; Kholodenko, 2002; Polo and Di Fiore, 2006; Sorkin and
Von Zastrow, 2002; Disanza et al., 2009; Sandilands and Frame,
2008) which influences biological outcomes (Zhang et al., 2000).
Alternatively, recent evidence suggests that for at least some
RTKs, signalling primarily occurs immediately following ligand
binding prior to endocytosis (Sousa et al., 2012; Brankatschk
et al., 2012). It is also possible that regulated endocytosis and
intracellular trafficking of activated RTKs shape the identity of
the signal as confinement within intracellular compartments
provides a mechanism for regulating the composition of receptor-
associated protein complexes. These considerations place
emphasis on understanding the molecular mechanisms that
coordinate activated RTK signalling and trafficking as key
determinants of the biological outcomes of receptor activation.
Fibroblast growth factor receptors (FGFRs) represent a
subfamily of 4 highly conserved RTKs (FGFR1, FGFR2,
FGFR3 and FGFR4) that regulates fundamental cellular
processes, including proliferation, differentiation and
angiogenesis (Burgess and Maciag, 1989; Basilico and
Moscatelli, 1992). FGFR activation initiates signalling through
a number of pathways including the well characterised Ras/Raf/
ERK and PI3 kinase/PDK/Akt pathways (Mason, 1994). Of
particular interest is the occurrence of somatic or germ-line
mutations in FGFRs which modify the dynamics of signal
propagation via mechanisms such as hyper-sensitivity of kinase



















amplification (Grose and Dickson, 2005; Wesche et al., 2011;
Turner and Grose, 2010; Beenken and Mohammadi, 2009). These
findings indicate that understanding the mechanisms of FGFR
endocytosis and trafficking, and their impact on signalling
dynamics, is an important goal in understanding both
pathological and physiological FGFR biology. We have
previously demonstrated a critical role for non receptor tyrosine
kinases of the Src family (SFKs) in shaping FGFR trafficking and
signalling dynamics (Sandilands et al., 2007). Src is recruited to
activated fibroblast growth factor receptor complexes through the
adaptor protein factor receptor substrate 2 (FRS2) at the plasma
membrane. This localisation requires both active Src and FGFR
kinases, which are interdependent. Internalization of activated
FGFRs involves release from complexes containing activated Src
and trafficking into multiple intracellular compartments
including RhoB and Rab5 endosomes via a mechanism(s)
which require an intact actin cytoskeleton (Sandilands et al.,
2007). Chemical and genetic inhibition studies showed strikingly
different requirements for Src family kinases in FGFR-mediated
signalling; activation of the phosphoinositide-3 kinase–Akt
pathway is severely attenuated, whereas activation of the
extracellular-signal-regulated kinase pathway is delayed in its
initial phase and fails to attenuate. These findings show that Src
kinase activity and Src substrates that mediate exit of activated
FGFRs from the plasma membrane are critical determinants of
the early phases of FGFR signal propagation.
In detailing Src substrates that are phosphorylated in the early
phases of FGFR activation, in order to identify candidates
for mediating Src-regulated trafficking, we identified the
multifunctional scaffolding protein Eps8 as a prominent target
of Src kinase activity (Cunningham et al., 2010). Eps8 is an
attractive subject for further scrutiny as it has well documented
roles in regulating the actin cytoskeleton (Provenzano et al.,
1998) and has been implicated in trafficking of the epidermal
growth factor receptor (EGFR) (Di Fiore and Scita, 2002).
Furthermore, EGFR signalling through Src has previously been
shown as a mechanism for regulating the cellular distribution of
clathrin (Wilde et al., 1999). It is accordingly of interest to
understand the functions of Eps8 in regulating FGFR trafficking
and signalling dynamics.
In this study, we have performed a detailed series of analyses
to investigate the mechanisms responsible for the coordinated
trafficking and signalling of activated FGFR. We have
specifically characterised the mechanisms controlling FGFR
endocytosis and endocytic trafficking in the early phases of
FGFR activation and in particular we have focused on the role of
Src acting through Eps8. Eps8 is thus identified as a key mediator
of the early phases of activated FGFR trafficking and signalling
relevant to regulation of clathrin-mediated endocytosis,
trafficking out of the early endosome into the perinuclear
recycling compartment, and FGF-mediated pErk signalling.
Results
FGFR is internalized though an FGFR-kinase- and
dynamin-dependent pathway
Different pathways have been implicated in the endocytosis of
activated RTKs (von Zastrow and Sorkin, 2007; Le Roy and
Wrana, 2005). Thus, we first set out to document the mechanism
by which FGFR is trafficked following activation. We employed
live-cell confocal microscopy to analyse the trafficking of
activated FGFR2 in HeLa cells, which express very low levels
of endogenous FGFR2 (Ahmed et al., 2008), using a GFP-tagged
form of FGFR2 which was previously validated in published
studies from John Ladbury’s laboratory (Schu¨ller et al., 2008). As
depicted in Fig. 1A, live-cell confocal imaging demonstrates that
following FGF stimulation, FGFR2–GFP undergoes rapid
internalization from the plasma membrane and eventually
traffics to a peri-nuclear endocytic compartment. This
redistribution away from the cell periphery did not occur in the
absence of ligand addition, and SU5402, a potent inhibitor of
FGFR kinase activity, completely prevented FGF stimulated
internalization (Fig. 1A,B) (Sun et al., 1999). Therefore, the
cellular localisation and behaviour of GFP-tagged FGFR2
reflects that of endogenous protein. Thus, we have applied this
quantitative and robust assay for trafficking of activated RTKs in
live cells to the analysis of the routes of FGFR endocytosis and
endocytic trafficking.
Several endocytosis pathways have been implicated in the
internalization of activated FGFRs (Marchese et al., 1998;
Citores et al., 1999; Belleudi et al., 2007; Gleizes et al., 1996;
Haugsten et al., 2011). The large GTPase dynamin has been
clearly demonstrated to be a crucial regulator of numerous
endocytosis pathways (Doherty and McMahon, 2009). Therefore,
we assessed whether inhibition of dynamin function with the
potent dynamin inhibitor Dynasore affected the ligand induced
endocytosis of FGFR (Macia et al., 2006). Importantly, control
endocytosis studies verified the efficacy of Dynasore treatment in
our systems (supplementary material Fig. S1A). As depicted in
Fig. 1C,D, treatment with Dynasore completely prevented
internalization of FGFR following FGF stimulation. Therefore,
activated FGFRs undergo dynamin-dependent endocytosis.
FGFR is internalized through clathrin-mediated
endocytosis
Two of the main endocytosis pathways that are dynamin
dependent include clathrin-mediated endocytosis and entry via
caveolae (Doherty and McMahon, 2009). We employed an
RNAi-based approach utilising previously published siRNA
which we have previously employed to silence expression of a-
adaptin, a critical component of the clathrin-mediated
endocytosis machinery, in HeLa cells (Rappoport and Simon,
2008; Rappoport and Simon, 2009), or caveolin1 (Li et al., 2012),
which is required for caveolae formation (Rothberg et al., 1992).
Control experiments revealed that a-adaptin siRNA treatment
significantly inhibited transferrin endocytosis (supplementary
material Fig. S1B) and potently reduced expression of a-adaptin
(supplementary material Fig. S1C). Similarly, siRNA targeting
caveolin1 significantly inhibited endocytosis of cholera toxin B
sub-unit (supplementary material Fig. S2A) and decreased
caveolin1 protein levels (supplementary material Fig. S2B).
Importantly, these siRNA reagents did not reduce expression of
control protein. Therefore, the utility of these inhibitory strategies
has been sufficiently validated in our systems for usage in live-
cell imaging studies.
As demonstrated in Fig. 2A,B, treatment with a-adaptin
siRNA clearly prevented endocytosis of FGFR following FGF
treatment. However, silencing of caveolin1 expression had no
effect on the internalization of FGFR following stimulation
(Fig. 2C,D). Thus, these results show that active FGFR enters
cells via clathrin-mediated endocytosis and not through caveolae.
In order to verify the potential for clathrin-mediated
endocytosis of activated FGFR we performed a series of


















colocalisation studies with known markers for these same two
endocytosis pathways. Total internal reflection fluorescence
(TIRF) microscopy permits selective illumination of the
plasma-membrane-associated region with a depth of penetration
of only ,100 nm (Axelrod, 2008; Mattheyses et al., 2010) and
has emerged as the technique of choice for imaging trafficking
Fig. 1. Active FGFR is internalized
through dynamin-dependent endocytosis.
HeLa cells transiently transfected with
FGFR2-GFP were incubated for 5 minutes in
the presence or absence of SU5402 (A) or for
30 minutes in the presence or absence of
Dynasore inhibitor (C) and imaged using
confocal live-cell microscopy at 37 C˚ for
30 minutes following stimulation with FGF2
+ heparin. The first and the last frames are
shown, corresponding to the situations before
and after FGF2 treatment, respectively. Scale
bars: 5 mm. (B,D) The experiments shown in
A and C were performed in many cells and
the relative FGFR2–GFP intensity in the PM
region of the cells was calculated (as
described in the Materials and Methods) for
each frame of the time-lapse sequence and
plotted as a function of time (means 6
s.e.m., n514 cells).
Fig. 2. Active FGFR enters cells by
clathrin-mediated endocytosis and not
through caveolae. HeLa cells were co-
transfected with FGFR2–GFP and a-adaptin
siRNA (A) or caveolin1 siRNA (C) and
confocal live-cell microscopy was
performed at 37 C˚ for 30 minutes following
stimulation with FGF2 + heparin. Scale bars:
5 mm. (B,D) The experiments shown in A
and C were performed in many cells and a
quantification of FGFR2–GFP intensity in
the PM region of the cells as function of
time was performed (means 6 s.e.m.,
n510 cells).


















processes at the plasma membrane such as endocytosis
(Rappoport, 2008), and the dynamics of activated RTKs
(Rappoport and Simon, 2009). As depicted in Fig. 3, TIRF
microscopy reveals that following FGF stimulation FGFR2–GFP
significantly colocalises with clathrin–dsRed (Fig. 3A,B), a
previously validated marker for sites of clathrin-mediated
endocytosis (Engqvist-Goldstein et al., 2001). Furthermore,
consistent with our RNAi studies (Fig. 2), no significant
colocalisation was observed between FGFR and a red-tagged
caveolin1 fusion protein known to mark caveolae at the cell
surface (Damm et al., 2005). Therefore, these two lines of
evidence support the conclusion that activated FGFR enters cells
primarily via clathrin-mediated endocytosis. It should be noted
though that, as in our previous studies of EGFR trafficking by
TIRF microscopy (Rappoport and Simon, 2009), colocalisation
of activated FGFR and clathrin at the plasma membrane persists
following time points where a majority of the receptor has been
internalised. This could either suggest differences between
endocytosis kinetics between the adherent and lateral plasma
membranes, or reflect the presence of a population of growth
factor receptor that does not undergo endocytosis following
activation, possibly signalling through clathrin-coated pits
(CCPs).
Live-cell TIRF microscopy can be employed to visualise the
dynamics of RTKs at the plasma membrane, and our previous
results demonstrated that following activation EGFR clusters at
pre-formed CCPs prior to endocytosis (Rappoport and Simon,
2009). Three non-mutually exclusive hypothesis could describe
the dynamics leading to colocalisation of activated FGFR and
clathrin: FGFR could be recruited to CCPs, CCPs could form at
the sites of receptor clustering, and clathrin and FGFR could
accumulate simultaneously. When two-colour live-cell TIRF was
performed on cells expressing FGFR2–GFP and clathrin–dsRed,
it was observed that the vast majority of receptor clusters form at
the sites of pre-existing clathrin (Fig. 4). In nearly all cases
clathrin was observed at the site where subsequently FGFR
would cluster. Thus, it seems that recruitment to pre-existing
CCPs represents an emerging paradigm for the dynamics of
activated RTKs.
FGFR activation promotes clathrin-mediated endocytosis
through Src and Eps8
Previous evidence has identified Src as involved in the
redistribution of clathrin to the cell periphery following RTK
activation (Wilde et al., 1999). Therefore, we assessed whether
FGFR stimulation regulated clathrin-mediated endocytosis. As
depicted in Fig. 5, stimulation of cells with FGF led to a striking
increase in the number of clathrin spots on the plasma membrane
(Fig. 5A,B). Furthermore, this also increased the density of
endocytosis events as gauged by established TIRF microscopy
based criteria (Fig. 5D) (Rappoport, 2008). Interestingly, FGF
treatment did not result in an increase in transferrin entry,
Fig. 3. Activated FGFR colocalises with clathrin at the
plasma membrane but not with caveolin1. HeLa cells
co-transfected with FGFR2–GFP and clathrin–dsRed
(A) or caveolin1–mRFP (C) were stimulated with FGF2 +
heparin for 15 minutes, then fixed and analysed using
dual-colour TIRF microscopy. Higher-magnification
images (insets) of selected regions of the cells show
overlap of FGFR and clathrin/caveolin1 in yellow. Scale
bars: 5 mm. (B,D) Quantification of colocalisation was
performed by analysing the overlap of each clathrin or
cavolin1 spot with an FGFR one. A control of random
colocalisation is also shown (means 6 s.e.m., n524 cells).
*P,0.05; **P,0.01; ***P,0.001.


















suggesting that the increased endocytosis observed following
FGFR activation may reflect a cargo specific pathway
(supplementary material Fig. S3).
The increase in clathrin-mediated endocytosis was a direct
consequence of receptor activity, and not an alternative effect of
FGF treatment, as SU5402 completely abrogated the ability of
Fig. 4. Activated FGFR clusters at sites of pre-formed
clathrin-coated pits. HeLa cells co-expressing FGFR2–GFP
and clathrin–dsRed were imaged using simultaneous two-
colour TIRF microscopy at 37 C˚ (1 frame/30 sec) after
stimulation with FGF2 + heparin. (B) Selected frames from a
time-lapse sequence of two FGFR spots (top) and two clathrin
spots (middle), and the merged images (bottom) showing the
overlap of the two channels in yellow. (C) The kymographic
representation of the spots shown in B reveals that FGFR
appears in the TIRF field and colocalises with pre-existing
clathrin. (A) Quantification of the percentage of clathrin
clusters forming at pre-existing FGFR spots, of FGFR spots
recruited at pre-formed clathrin clusters or FGFR and clathrin
clustering simultaneously at the plasma membrane (means 6
s.e.m., n533 cells). *P,0.05; **P,0.01; ***P,0.001.
Fig. 5. FGFR activation promotes
clathrin-mediated endocytosis via Src
and Eps8. (A–C) HeLa cells transiently
expressing FGFR2–GFP and clathrin–
dsRed and incubated in the presence or
absence of SU5402 (5 minutes), Dasatinib
inhibitor (30 minutes) or treated with Eps8
siRNA, were analysed using TIRF
microscopy before and 30 minutes after
stimulation with FGF2 + heparin.
(A) Upon FGF stimulation, cells show a
significant increase in the number of
clathrin spots on the plasma membrane.
Scale bars: 5 mm. (B,C) Quantification of
the clathrin spots for the different
conditions described above reveals that the
FGF-dependent increase of clathrin at the
plasma membrane is both Src and Eps8
dependent, and requires the full kinase
activity of the receptor. (D) HeLa cells
expressing FGFR2–GFP and Clathrin–
dsRed were imaged using live-cell TIRF
microscopy at 37 C˚ for 2 minutes
(1 frame/200 msec) before and 30 minutes
after stimulation with FGF2 + heparin.
Quantification of the clathrin spots
disappearing from the TIRF field shows a
significant increase in the density of
endocytic events upon FGF stimulation
(means 6 s.e.m., n530 cells for each
condition in B and C, n524 cells in D.
*P,0.05; **P,0.01; ***P,0.001.
(E) Cellular extracts from HeLa cells
transfected with myc–Eps8 (where
indicated) were immunoprecipitated with
anti-myc, resolved by SDS-PAGE and
analysed by immunoblotting for the levels
of specified proteins.


















FGF addition to increase clathrin spot number at the plasma
membrane (Fig. 5B). However, as SU5402 treatment in
unstimulated cells did not alter the steady state number of
clathrin spots on the cell surface, it can be inferred that basal
FGFR signalling does not regulate the baseline level of clathrin-
mediated endocytosis. Treatment with the Src family kinase
inhibitor Dasatinib, which we have previously shown inhibits
Src-dependent FGFR signalling and trafficking events
(Sandilands et al., 2007), significantly inhibited the ability of
FGFR stimulation to increase clathrin spot numbers (Fig. 5B).
However, Dasatinib treatment in unstimulated cells did not
reduce the number of CCPs, suggesting that SFK activity is not
required for constitutive endocytosis.
Our previously published work identified that Eps8 is
phosphorylated in a Src-dependent manner following FGFR
activation (Cunningham et al., 2010). Furthermore, Eps8 has
been implicated as playing a role in clathrin-mediated
endocytosis (Taylor et al., 2011). Consistent with these
observations, treatment with Eps8 siRNA completely prevented
the increased number of clathrin spots following FGFR activation
(Fig. 5C). Importantly, the sequence employed to silencing Eps8
was employed in previously published studies from the
laboratory of Giorgio Scita (Disanza et al., 2006), and western
blot analysis revealed that siRNA targeting Eps8 potently
reduced Eps8 protein levels without affecting expression on
negative control protein, tubulin (supplementary material Fig.
S4A). Therefore, FGFR signalling through Src to Eps8 appears to
be important in recruiting new clathrin at plasma membrane,
consequently promoting clathrin-mediated endocytosis. This
provides evidence for a biologically relevant link between
FGFR-mediated signalling and membrane trafficking mediated
through Src and Eps8. Furthermore, we have performed similar
studies in LNCap cells (supplementary material Fig. S5), which
have previously been shown to endogenously express FGFR2
(Carstens et al., 1997). These studies revealed that in the absence
of expression of GFP-tagged FGFR treatment of cells with FGF2
resulted in a significant increase in plasma membrane clathrin
spot number. Therefore, these results demonstrate this effect is
not cell line specific, and can occur via signalling through
endogenous FGFR2.
In order to verify the suggested link between Eps8 and
clathrin-mediated endocytosis we performed a series of
biochemical studies. Co-immunoprecipitation analyses
demonstrated that Eps8 associates with clathrin heavy chain, a-
adaptin and dynamin2 (Fig. 5E), all proteins involved in clathrin-
mediated endocytosis (Doherty and McMahon, 2009). This
suggests that Eps8 is capable of being incorporated into a
complex with several members of the endocytosis machinery,
further supporting its role in early phases of trafficking following
receptor activation. These associations were also observed in
similar studies performed in HEK293 cells, the proteomic
platform we previously employed to identify the connection
between FGFR, Src and Eps8 (Cunningham et al., 2010)
(supplementary material Fig. S6). Furthermore, in this model
we observed that interactions between Eps8 and the machinery
for clathrin-mediated endocytosis occur with and without FGF
stimulation.
FGFR early endocytic trafficking requires SFK kinase
activity
As the above data suggesting a role for Src and Eps8 in the early
phases of FGFR signalling and clathrin-mediated endocytosis, we
studied the effects of Src inhibition on trafficking of activated
FGFR. As depicted in Fig. 6, treatment with Dasatinib resulted in
Fig. 6. Inhibition of Src kinase activity and
silencing of Eps8 impair the trafficking of
FGFR. (A) HeLa cells transiently expressing
FGFR2–GFP were incubated for 30 minutes
in the presence or absence of Dasatinib and
imaged by confocal live-cell microscopy at
37 C˚ for 30 minutes following stimulation
with FGF2 + heparin. (C) Eps8 knockdown
cells (Eps8 shRNA) transiently expressing
FGFR2–GFP were stimulation with FGF2 +
heparin and imaged as in A. The first and the
last frame of the time-lapse sequences are
shown in A and C. Scale bars: 5 mm. Higher-
magnification images of selected regions
from the cells (insets) show an atypical
peripheral localisation of FGFR-containing
vesicles. (B,D) The quantification of FGFR2–
GFP intensity in the PM region of the cells as
a function of time shows an impaired
trafficking of FGFR in both Src-inhibited and
Eps8shRNA cells (means 6 s.e.m.,
n516 cells).


















pronounced effects on the behaviour of FGFR2–GFP following
FGF stimulation. Almost complete inhibition of redistribution of
FGFR from the cell periphery was observed (Fig. 6A,B).
However, high magnification imaging of the plasma-
membrane-associated region (see Fig. 6A, inset) revealed the
presence of numerous peripheral puncta containing FGFR
following stimulation. This would support our evidence for a
role of Src-kinase-dependent processes in regulating early
endocytic trafficking of activated FGFR.
The role of Eps8 in endocytic trafficking of FGFR
Given the potential role of Eps8 as a downstream effector of Src-
kinase-mediated processes, we next studied the consequences of
Eps8 depletion on activated FGFR trafficking. In order to assess a
role for Eps8 in this process, we made use of a HeLa cell line
engineered with stable silencing of Eps8 expression which was
previously validated in published studies from the laboratory of
Giorgio Scita (Disanza et al., 2006). Western blotting studies
confirmed potent and specific silencing of Eps8 in these cells,
relative to control (supplementary material Fig. S4B). Similar to
our observations in cells treated with the Src inhibitor
(Fig. 6A,B), shRNA-mediated reduction in the expression of
Eps8 also inhibited trafficking of activated FGFR away from the
cellular periphery and towards the perinuclear region
(Fig. 6C,D). Furthermore, peripheral FGFR-positive puncta
were observed in Eps8 knockdown cells, identical to those
observed following Dasatinib treatment (see Fig. 6C, inset).
Interestingly, an effect of Eps8 depletion was not apparent at the
earliest time points following FGF addition; accumulation of
FGFR in a peripheral compartment, rather than direct inhibition
of FGFR endocytosis was evident. Thus, inhibition of Src
function and silencing of Eps8 result in similar effects on FGFR
trafficking further supporting a mechanistic connection between
FGFR activation, Src kinase activity and Eps8 function,
specifically localised in a peripheral endocytic compartment.
In order to further characterise the potential localisation of
Eps8 action on the endocytic trafficking of FGFR we
simultaneously visualised both in cells at various times
following FGF addition. As depicted in Fig. 7, prior to
stimulation both FGFR and Eps8 are observed primarily close
to the lateral plasma membrane, consistent with our other
observations. However, while FGFR and Eps8 colocalise to a
Fig. 7. During early stages of trafficking Eps8 colocalises with FGFR and is required for signal transduction through the MAPK cascade. HeLa cells
transiently expressing FGFR2–GFP and Eps8–mCherry were either stimulated with FGF2 + heparin for 10 or 30 minutes, or not stimulated, then fixed and
analysed using confocal microscopy. (A) During the early stages of activation (10 min FGF), FGFR primarily localises in early endosomal compartments, where it
colocalises with Eps8. 30 minutes after FGF addition, FGFR redistributes to the perinuclear region, whereas Eps8 still resides in peripheral compartments, just
beneath the plasma membrane. Scale bars: 5 mm. (B) Quantification demonstrates significant colocalisation of FGFR and Eps8 only during early phases of
receptor activation, where they both localise in early endocytic compartments (means 6 s.e.m., n514 cells). (C) Eps8 knockdown and vector control HeLa cells
transiently expressing FGFR2–GFP were lysed following stimulation with FGF2 + heparin for the indicated times. Cellular extracts where resolved by SDS-PAGE
and analysed by immunoblotting for the levels of the specified proteins. The time course of Erk phosphorylation in response to FGF shows a significant
attenuation of p44 ERK signal at early times (5 minutes) in Eps8 knockdown cells. (D) Quantification of p44 pERK levels following FGF stimulation in Eps8
knockdown (blue) and vector control HeLa (green) cells (means 6 s.e.m., n55 experiments) by densitometric scanning of western blots. *P,0.05;
**P,0.01; ***P,0.001.


















very large degree in peripheral vesicles 10 minutes post-
stimulation, once FGFR traffics into the juxtanuclear
compartment this coincidence is lost. Quantification revealed
that 30 minutes following addition of FGF, Eps8 is retained at the
periphery and no longer colocalises with the juxtanuclear pool of
FGFR (Fig. 7B). Similarly, Eps8 colocalises with EEA1, a
marker for early endosomes (Stenmark et al., 1996) (data not
shown). Therefore it appears that Eps8 resides in the early
endocytic system, and that activated receptors move through this
compartment following endocytosis.
To further elucidate the site of action of Src/Eps8 in FGFR
trafficking we performed a series of other colocalisation studies.
As depicted in supplementary material Fig. S7, triple
colocalisation of activated FGFR, following 10 minutes FGF
treatment, Eps8, and transferrin, following a 5 minute incubation
places Eps8 in a common early endocytic compartment shared by
activated growth factor receptors and transferrin/transferrin
receptor. Additionally, in supplementary material Fig. S8
colocalisation between Eps8 and constitutively active Src in the
cell periphery, further support our evidence of an early endocytic
compartment regulated by Src and Eps8.
The role of Eps8 in FGFR signalling
As we have clearly identified a role for Eps8 in the early
endocytic trafficking of FGFR, we next tested whether Eps8
regulated FGFR signalling as well. As depicted in Fig. 7C,D,
stimulation with FGF results in a rapid appearance of the p44
form of activated ERK which reaches maximum amplitude at
5 minutes and then declines. In this system, the p42 form of ERK
exhibits tonic basal activation and does not respond to FGF
stimulation. In fact p42/ERK is apparent in non-transfected HeLa
cells subjected to overnight serum starvation (supplementary
material Fig. S9). In cells stably silenced for Eps8 expression the
FGF-mediated activation of p44 ERK was blunted during the
initiating (5 minute) phase of the FGF response. Thus, these
findings show that functional Eps8 is required for early phase
activation of the Ras/Raf/ERK pathway during the period in
which activated FGFRs are recruited away from the plasma
membrane. This finding also suggests that activated FGFR can
connect to the Ras/Raf/ERK pathway in an Eps8-independent
manner which results in lower amplitude signals. Thus this
suggests that Eps8 coordinates the signalling and trafficking of
FGFR immediately following activation.
The role of Eps8 in trafficking FGFR out of the early
endosome
In order to further characterise the role of Eps8 in FGFR
trafficking, we performed a series of colocalisation studies with
well characterised markers within the endocytic system. As in our
previous live-cell imaging studies, 30 minutes following
activation FGFR was observed to localise to an intracellular
region adjacent to the nucleus (Fig. 8A). Thus, the extent of
colocalisation between FGFR and EEA1, was very low
30 minutes post-stimulation (Fig. 8B). However, in the Eps8
knockdown cells the extent of colocalisation between FGFR and
EEA1 was significantly higher (Fig. 8B), suggesting that Eps8
functions to permit exit of FGFR from peripheral early
endosomes. Similarly, while clear colocalisation was observed
between FGFR and Rab11 (Fig. 8C), a marker for the peri-
nuclear recycling compartment (Ullrich et al., 1996), in control
cells 30 minutes post-stimulation, this was significantly reduced
in the Eps8 knockdown cells (Fig. 8D). Finally, we performed
similar studies employing Lysotracker as a marker for endocytic
degradative compartments (Fig. 8E,F), and found that silencing
of Eps8 significantly reduced colocalisation of FGFR and
Lysotracker 30 minutes post-stimulation. Finally, super-
resolution imaging of FGFR–GFP in Dasatinib treated cells
30 minutes after FGF addition revealed clearly the presence of
FGFR in peripheral diffraction limited puncta (supplementary
material Fig. S10). Therefore, these results demonstrate that Eps8
is required for the trafficking of activated FGFR out of the early
endocytic system and into the peri-nuclear recycling
compartment and degradative compartment(s).
Discussion
Growth factor receptors undergo regulated internalization from
the cell surface in response to ligand binding (von Zastrow and
Sorkin, 2007; Le Roy and Wrana, 2005). Endocytosis and
subsequent degradation represent strategies to attenuate
signalling of RTK, and alterations in receptor trafficking have
emerged as a mechanism of oncogenic activation (Peschard and
Park, 2003). Here we have applied imaging based assays for
studying endocytosis and trafficking of FGFRs with cells
expressing a previously validated GFP-tagged FGFR2 (Schu¨ller
et al., 2008). Through use of this system we have demonstrated
the interplay between RTK signalling and trafficking, and
identified a mechanistic role for Eps8 in mediating clathrin-
mediated endocytosis, endocytic trafficking, and MAP kinase
signalling. We have demonstrated that receptor trafficking is
regulated through signalling transduction pathways downstream
of receptor activation, and that the location of the activated
receptor within the endocytic system has significant implications
on the amplitude of signalling readouts.
Although FGFs are extremely relevant in both development
and cancer progression, very little is known about FGFR
trafficking (Marchese et al., 1998; Citores et al., 1999; Belleudi
et al., 2007; Gleizes et al., 1996; Haugsten et al., 2011). Our data
have shown that internalization of FGFR was severely reduced in
cells treated with the dynamin inhibitor Dynasore (Fig. 1),
indicating that endocytosis of activated receptor occurs through a
dynamin-dependent pathway. Using a siRNA approach we
observed a complete block of FGFR endocytosis in cells
silenced for a-adaptin, whereas no effect was detected in cells
treated with caveolin1 siRNA (Fig. 2). We further confirmed
these observations by analysing the colocalisation of FGFR with
clathrin or caveolin1 at the plasma membrane using TIRF
microscopy. Following stimulation, activated FGFR significantly
colocalises with clathrin at the cells surface, while no
colocalisation with caveolin1 was observed (Fig. 3). Thus,
these results identified clathrin-mediated endocytosis as the
major pathway for FGFR internalization. Further analyses via
live cell TIRF microscopy demonstrated that, like activated
EGFR (Rappoport and Simon, 2009), following stimulation
FGFR is recruited into pre-formed CCPs (Fig. 4), suggesting that
this may be a mechanism conserved across multiple different
RTKs.
The next phase of our studies was to characterise mechanistic
links between FGFR signalling and trafficking. Src plays a
central role in FGFR signalling pathway and has been previously
suggested to regulate FGFR trafficking (Sandilands et al., 2007).
Previous analyses from our laboratory identified putative Src
targets involved in the regulation of FGFRs signalling and


















trafficking (Cunningham et al., 2010). In particular the protein
Eps8, previously implicated in vesicle trafficking (Lanzetti et al.,
2000), was identified as a Src-dependent kinase substrate
phosphorylated in response to FGF stimulation. Therefore, we
analysed potential roles for Eps8 in the trafficking and signalling
of activated FGFR.
Previously it was shown that EGFR activation, signalling
through Src, increased the peripheral accumulation of clathrin
(Wilde et al., 1999). Our work demonstrates that FGFR activation
increases both the number of CCPs and the events of clathrin-
mediated endocytosis (Fig. 5). Furthermore, we have
demonstrated that Src kinase activity and Eps8 are required for
the increase in CCP number following FGFR activation (Fig. 5).
Interestingly though, while FGFR activation stimulated clathrin-
mediated endocytosis, it did not increase transferrin uptake
(supplementary material Fig. S3). Thus, the route of entry for
activated RTKs may exist as a cargo specific pathway.
Consistent with live cell imaging studies (Taylor et al., 2011),
our biochemical studies demonstrated that Eps8 interacts with the
clathrin-mediated endocytosis machinery (Fig. 5). Interestingly,
similar studies in HEK293 cells demonstrated these interactions
are not FGF2 stimulus dependent (supplementary material Fig.
S6). However, we have also identified roles for Src and Eps8 in
the further endocytic trafficking of FGFR. Following Dasatinib
treatment, FGFR containing vesicles were observed to
accumulate at the cell periphery, confirming the role for Src in
the early endocytic trafficking of FGFRs (Fig. 6). Similarly, in
Eps8 knockdown cells we observed a Dasatinib-like phenotype: a
strong inhibition of FGFR trafficking with a pool of receptor
localised in a peripheral punctuate compartment (Fig. 6). Thus,
this is consistent with our hypothesis that Eps8 is a Src-dependent
regulator of FGFR trafficking within the early endocytic system.
Further supporting a role for Eps8 in exit from the early
endocytic system, during the early stages of trafficking FGFR
significantly colocalises with Eps8 just beneath the plasma
membrane (Fig. 7). Furthermore, Eps8 colocalised with FGFR
and transferrin in peripheral early endosomes (supplementary
material Fig. S7), as well as with constitutively active Src
(supplementary material Fig. S8). However, 30 minutes post-
stimulation the juxtanuclear pool of FGFR clearly did not
colocalise with Eps8 which was retained in a peripheral
compartment (Fig. 7). Similarly, exit from the EEA1 early
Fig. 8. Eps8 is required for the trafficking of activated FGFR out of
the early endocytic system and into the peri-nuclear recycling and
late degradative compartments. Eps8 knockdown and vector control
HeLa cells transiently expressing FGFR2–GFP were fixed following
stimulation with FGF2 + heparin for 30 minutes, immunostained for
EEA1 (A) or Rab11 (C) or treated with LysoTracker Red (E) and
analysed by confocal microscopy. Higher-magnification images of
selected regions from the cells (insets) show that in Eps8 knockdown
cells, where receptor trafficking is impaired, FGFR is retained in the
peripheral compartment (EEA1) and prevented from sorting to the peri-
nuclear recycling compartment (Rab11) and to the lysosomal
degradative compartment (LysoTracker). Scale bars: 5 mm.
(B,D,F) Colocalisation between FGFR and EEA1, Rab11 or
LysoTracker was quantified in control cells as 0.1960.02, 0.5760.04,
and 0.7460.01, respectively, and in Eps8 knockdown cells as
0.3660.04, 0.2460.05 and 0.1860.01, respectively (Pearson’s
correlation coefficient; means 6 s.e.m., n518 cells).


















endosome was significantly reduced when Eps8 expression was
silenced (Fig. 8). Finally, 30 minutes post-stimulation FGFR was
found to localise to the Rab11-positive peri-nuclear recycling
compartment, as well as degradative compartments, in stimulated
control cells, and this was prevented in Eps8 knockdown cells
(Fig. 8). Thus, activated receptors traffics through the Eps8/
EEA1-positive peripheral compartment en route to the PNRC and
late endosome/lysosome, and in the absence of Eps8 this is
prevented.
Finally, we sought to determine if there is a concomitant
feedback into FGFR2 signalling mediated through Eps8.
Silencing of Eps8 expression had significant effects on a burst
in Erk activation through the p44 form immediately following
receptor activation (Fig. 7), suggesting that, consistent with
recent work with EGFR (Sousa et al., 2012; Brankatschk et al.,
2012), FGFR signalling through the MAP kinase pathway can
occur prior to/during receptor endocytosis. Importantly, the p42/
Erk band revealed in our studies, which was not Eps8 sensitive, is
chronically active in HeLa cells (supplementary material Fig.
S9). Finally, super-resolution imaging on a Leica gSTED system
further elucidated the site of Eps8/Src-dependent FGFR
trafficking (supplementary material Fig. S10). In Dasatinib
treated cells FGFR clearly resides in peripheral puncta.
Therefore, taken together these results identify Eps8 as a key
mediator of activated FGFR trafficking and signalling, and
identify the peripheral early endocytic compartment as a key
crossroads in the regulation of RTKs.
The interplay between receptor tyrosine kinase signalling and
trafficking has been emerging an area critical to understanding
fundamental aspects of cell biology as well as how mis-
regulation of either could potentially lead to pathological
conditions, such as developmental defects or chronic disease.
Our studies point to a response arc leading from RTK activation
through Src via Eps8. Evidence supporting this hypothesis has
been gained from a variety of studies, and is based upon work in
other signalling systems, suggesting potential widespread
significance. In our studies we have demonstrated that
following activation FGFR enters the cell via clathrin-mediated
endocytosis. FGF stimulation increases the number of CCPs, and
events of clathrin-mediated endocytosis. Furthermore, both the
FGF-dependent increase in clathrin at the plasma membrane and
the early endocytic trafficking of activated FGFR depend upon
Src and Eps8. FGFR traffics through an Eps8-positive early
endocytic compartment on the way to the PNRC and lysosome,
and in the absence of Eps8, FGFR is retained in peripheral early
endosomes. Eps8 is also required for early phase pErk activation,
placing this event early in the trafficking of activated FGFR.
Therefore, FGFR activation induces alterations in signalling and
trafficking that are mediated by Src acting through Eps8, and this
alters both early endocytic trafficking and downstream MAPK
signalling. Thus, the correlation between Src- and Eps8-
dependent FGFR signalling and trafficking suggests a direct
link between the two. However, validation and elucidation of the
direct mechanistic coupling between FGFR signalling and
trafficking and the precise role(s) of Src and Eps8 await further
work in this area. In conclusion, while our data suggest that
signalling through activated FGFR promotes clathrin-mediated
endocytosis, and that this effect depends on Src/Eps8, the initial
wave of FGFR endocytosis, although clearly clathrin dependant,
does not seem to critically rely upon Src/Eps8. Finally, as
constitutive endocytosis and the steady state production of
clathrin-coated vesicles do not seem to be Src/Eps8 dependant,
the endocytic cargo removed from the plasma membrane in FGF
treated cells mediated by Src/Eps8 remains presently elusive.
Materials and Methods
Plasmids, siRNA and antibodies
The construct encoding GFP-tagged FGFR2IIIc (FGFR2–GFP) was a gift from J.
Ladbury (M.D. Anderson Cancer Center, The University of Texas). DsRed-tagged
clathrin light chain A (clathrin-dsRed) was a gift from T. Kirchhausen (Harvard
Medical School, Boston, MA). Caveolin1-mRFP was a gift from A. Helenius (ETH
Institute of Biochemistry, Zurich, Switzerland). Eps8-mCherry was a gift from
Giorgio Scita (IFOM University of Milan, Milan, Italy). Constitutively active Src
was provided by Margaret Frame (Edinburgh Cancer Research UK Centre). siRNA
oligos targeting a-adaptin (sequence 59-AAGAGCAUGUGCACGCUGGCCA-39),
caveolin1 (SmartPool l-003467) and Eps8 (sequence 59-TGCAGACCC-
TAGTATACCG-39) were purchased from Dharmacon. Antibodies used were:
anti-Rab11 (Invitrogen); anti-EEA1 (Abcam); anti-caveolin1 (BD Biosciences);
anti-a-adaptin (Santa Cruz); anti-a-tubulin (Sigma); a-ERK1/2 and a-pERK (Santa
Cruz); a-Eps8 (Abcam); anti-phospho-Src family (Tyr416; Cell Signaling);
IRDye680 and IRDye800 conjugated secondary antibodies (Odyssey).
Cells and transfection
Eps8 shRNA and control shRNA HeLa cells were a gift from Giorgio Scita (IFOM
University of Milan, Milan, Italy). HeLa and LNCaP cells were propagated in
DMEM (Invitrogen) supplemented with 10% FBS (Labtech International) in a 5%
CO2 atmosphere at 37 C˚. DNA and siRNA transfection was performed by using
Lipofectamine 2000 transfection reagent (Invitrogen) according to the
manufacturer’s protocol. At 48 hours post-transfection, cells were serum-starved
for 30 min and then stimulated with 20 mg/ml Heparin (Sigma) and 50 ng/ml
FGF2 for the indicated times. For the inhibition assays cells were either treated
with 25 mM SU5402 (Calbiochem) for 5 min, 80 mM Dynasore (Sigma) for
30 min or 50 nM Dasatinib (Sellek Chemicals) for 30 min or treated as above in
the absence of drug before FGF stimulation. For live-cell imaging, cells were
washed once and the medium removed was replaced with prewarmed (37 C˚)
imaging medium [10 mM HEPES–Hank’s balanced salt solution (HBSS; Sigma)
pH 7.4].
Laser scanning confocal microscopy and total internal reflection
fluorescence microscopy
Confocal laser was performed with an inverted microscope (Eclipse Ti, Nikon
A1R) at 37 C˚ using a 606 1.45 NA oil-immersion objective and 12-bit CCD
camera (Ixon 1M EMCCD). GFP constructs were excited with an argon ion 457–
514 nm laser, mRFP and dsRed constructs with a Green Diode 561 nm laser.
Images were prepared with NIS-Elements Imaging Software version 3.2 (Nikon).
TIRF microscopy was performed with the system described above as well as with
an inverted microscope (IX81, Olympus) using a 606 1.49 NA oil-immersion
objective and a 12-bit CCD camera (ORCA-R2 C10600, Hamamatsu). GFP
constructs were excited with a 491-50 Diode type laser, dsRed constructs with a
561-50 DPSS type laser. Images were analysed and prepared with Xcellence
Advanced Lice Cell Imaging System version 1.1 (Olympus). Super-resolution
imaging was performed on a gSTED system (Leica) and image stacks were
deconvolved using Huygens linked within the Leica software.
Immunofluorescence
Cells grown on coverslips were fixed in 4% paraformaldehyde in TBS for 10 min,
washed in TBS/100 mM glycine and permeabilised with TBS/0.1% saponin/
20 mM glycine. After blocking with TBS/0.1% saponin/10% FCS, cells were
incubated with primary antibodies, then washed and incubated with secondary
antibodies. After staining, the coverslips were mounted in Hydromount (National
Diagnostic) and imaged by using a Zeiss LSM 710 confocal microscope, a 406
1.3NA oil-immersion objective and a Transmission-Photomultiplier LSM T-PMT.
Each experiment was repeated a minimum of three times and an image that
represented the phenotype of most of the cells was selected. For lysosomal
staining, cells were incubated with 75 nM LysoTracker Red (Molecular Probes)
for 30 minutes and immediately imaged in imaging media at room temperature.
Transferrin and cholera toxin B uptake assay
Following serum-starvation for 30 min, cells were incubated at 37 C˚ in either
Alexa-Fluor-546–transferrin (Invitrogen), or Alexa-Fluor-555–cholera-toxin-B
(Invitrogen). Cells were then rinsed, fixed and analysed by using a Nikon
TE300 inverted epi-fluorescence microscope using an 6061.40 NA oil-immersion
objective and a cooled CCD camera (Hamamatsu C4742-98-12WRB). For the
triple colocalisation, HeLa cells were incubated with Alexa-Fluor-633–transferrin
(Invitrogen) for 5 minutes, in order to mark the early endosomes. Cells were then
rinsed, fixed and analysed using confocal microscopy.



















For the trafficking assays FGFR2–GFP intensity in the plasma-membrane-
associated region of the cells was calculated for each frame of the time-lapse
sequences (1 frame/5 min). From each time point, a background value was
subtracted, corresponding to the cytosolic fluorescence intensity before the
stimulation with FGF (time50 min). Cells were treated with a red membrane stain
(data not shown) in order to define the plasma-membrane-associated region. For
the colocalisation analysis, each spot of FGFR, clathrin, caveolin1 and Eps8 was
identified and a circle was drawn around it. Spots were identified as colocalising
when most of the fluorescence intensity of the pixels within the circular regions
fitted in both the channels. For quantification of transferrin and cholera toxin
uptake, cells randomly located on the coverslips were scanned at fixed intensity
settings below pixel-saturation, and the total cellular intensity was determined.
Data analysis was performed using either NIS-Elements Imaging Software version
3.2 (Nikon) or Xcellence Advanced Lice Cell Imaging System version 1.1
(Olympus).
Biochemical assays
Cultures of HeLa or Hek293T cells were lysed in lysis buffer (50 mM Tris-HCl
pH 7.4, 150 mM NaCl, 1% Triton TX-100, 1 mM sodium orthovanadate, 50 mM
sodium fluoride, 25 mM b-glycerophosphate) supplemented with complete mini
protease inhibitors cocktail (Roche). The extracts were resolved by a 4–12%
NuPAGE Bis-Tris SDS gel (Invitrogen) and transferred to Immobilon PVDF-FL
membrane (Millipore). The membrane was blocked in methanol and incubated
with primary antibodies overnight at 4 C˚. After washing in PBS 0.1% Tween-20
the membrane was incubated with secondary antibodies for 1 hour at room
temperature followed by washing and detected using an Odyssey infrared imaging
system (Li-COR). For the immunoprecipitation assay, cells were lysed and
prepared as described. The extracts were immunoprecipitated with dynabeads
(Invitrogen) crosslinked with anti-myc antibody. Supernatants were loaded on a 4–
12% NuPAGE Bis-Tris SDS gel (Invitrogen) and subjected to immunoblot
analysis with indicated antibodies. Quantification by densitometric scanning of
western blots was performed using Odyssey Application Software version 3.0 (Li-
COR). Since the primary antibodies used in this analysis detected both the 42 kDa
and 44 kDa form of ERK/pERK, two bands were visualized and captured. The
relative p44 phosphoERK levels shown in Fig. 7D were calculated by normalizing,
for each point of the time course, the relative optical density value of the p44
phosphoERKs band to the corresponding total p44 ERK value.
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